Insulet cuts 2026 revenue guidance, shares fall 20% after Q2 beat

What happened

Insulet Corporation reported second-quarter 2026 results on August 5 that exceeded revenue and adjusted EPS estimates. However, the company reduced its full-year 2026 constant-currency revenue growth guidance to 20%-22% from the prior range of 21%-23%, and specifically lowered its U.S. Omnipod growth outlook to 17%-19% from 20%-22%.

According to Reuters, CEO Jim Hollingshead attributed the weaker outlook to lower-than-expected retention and usage among type 2 diabetes patients in their first 90 days on the Omnipod system.

The filing

In its earnings press release, Insulet reported Q2 revenue of $801.7 million, up 23.5% year over year, and adjusted earnings per share of $1.66, both beating analyst estimates. The company's revised full-year guidance reflects expectations of a softer second half, particularly for U.S. Omnipod sales.

The press release provided the revised guidance ranges but did not detail the specific causes; the CEO's explanation was reported separately by Reuters.

Market reaction

Shares of Insulet (NASDAQ: PODD) fell 20.12% on August 5, closing at $133.26, according to market data. The decline erased roughly $5 billion in market capitalization following the guidance reduction.